Canada markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
19.07+0.26 (+1.38%)
At close: 04:00PM EDT
19.19 +0.12 (+0.63%)
After hours: 06:38PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close18.81
Bid19.05 x 200
Ask19.11 x 400
Day's Range18.84 - 19.73
52 Week Range12.32 - 32.10
Avg. Volume805,052
Market Cap914.906M
Beta (5Y Monthly)-0.49
PE Ratio (TTM)N/A
EPS (TTM)-2.17
Earnings DateAug 01, 2024 - Aug 05, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 13, 2012
1y Target Est103.00
  • Zacks

    Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross

    When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

  • GlobeNewswire

    Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

    $126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 mill

  • GlobeNewswire

    Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

    Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per ShareAUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distributed to its shareholders (the “Warrants”). Gross proceeds from the Warrants represents the issuance of